Lung Cancer
Conditions
Keywords
Lung Cancer
Brief summary
To describe the overall survival of advanced NSCLC in Latin America.
Detailed description
* To describe demographic and socioeconomic characteristics of patients newly diagnosed with advanced NSCLC * To describe diagnostic methods, pathological profile and disease stage at diagnosis of advanced NSCLC * To describe the practice patterns of therapeutic agents for treatment of advanced NSCLC * To describe treatment responses, progression and survival times. * To describe reasons for treatment discontinuation * To identify associations between patient demographics, socioeconomic, pathology, treatment sequences and overall survival; * To define the patient experience of advanced NSCLC and identify unmet needs in their diagnose and treatment.
Interventions
None listed
Sponsors
Bristol-Myers Squibb
Latin American Cooperative Oncology Group
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients aged 18 years or older; 2. Newly diagnosed Non-Small Cell Lung Cancer (NSCLC) during the period of the study (which includes 3 months prior to site activation by LACOG, although they can have received anti-cancer treatment during that time); 3. Histologically or cytologically confirmed advanced NSCLC: 1. Stage IIIB that progressed after curative therapy (chemoradiation and/or surgery); 2. Stage IV metastatic disease (de novo or distant relapse) 4. Any NSCLC histological subtype and molecular mutation; 5. Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis; 6. Patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted agents, immunotherapy) or palliative care; 7. Access to patient medical chart for data collection; 8. Willing and able to provide written informed consent and privacy authorization for the release of personal health information.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival of advanced NSCLC in Latin America | Annually, during 3 years | Time from randomization or initiation of treatment to patient death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Description of socioeconomic characteristics of patients newly diagnosed with advanced NSCLC | Annually, during 3 years | Description of the socioeconomical characteristics of the Latin America population with newly advanced NSCLC |
| Description of pathological profile of advanced NSCLC | Annually, during 3 years | Analysis of histology and molecular markers of advanced NSCLC |
| Description of the practice patterns of therapeutic agents for treatment of advanced NSCLC | Annually, during 3 years | Description of the practice patterns of therapeutic agents for treatment of advanced NSCLC |
| Description of the treatment responses | Annually, during 3 years | Description of the treatment responses |
| Description of Treatment discontinuation | Annually, during 3 years | Description of the reasons for treatment discontinuation |
Countries
Argentina, Brazil, Chile, Colombia, Mexico
Outcome results
None listed